Vicore Pharma (VICO) Cantor Global Healthcare Conference 2025 summary

Strategic positioning in IPF landscape

• Focused on late-stage clinical development for idiopathic pulmonary fibrosis (IPF), a disease with high unmet need and significant commercial potential.

• Believes current standard of care is inadequate in efficacy and tolerability, with opportunity for better therapies.

• Emphasizes a novel, upstream mechanism targeting alveolar epithelial type II cells to address fibrosis, inflammation, and vascular dysfunction.

• Mechanism aims to regenerate lung tissue, reduce pathological signaling, and improve vascular function.

• Positions itself as offering a more comprehensive approach compared to current and emerging therapies.

Industry landscape and recent developments

• Recent phase III successes in IPF include BI’s PDE4 inhibitor and United Therapeutics’ inhaled treprostinil, both showing slowed lung function decline.

• United’s therapy combines antifibrotic and vasodilatory effects, but Vicore’s approach adds epithelial repair and regeneration.

• New therapies are welcomed due to tolerability issues with current standards, but differentiation remains key.

Phase IIa AIR study findings

• Open-label, single-arm study in treatment-naive IPF patients, with a significant portion enrolled from India and the UK.

• Demonstrated a >200 ml mean increase in lung function over 36 weeks, with 65% of patients improving.

• Improvement was consistent across geographies and subgroups, with earlier-stage patients showing the strongest effects.

• Synthetic control arm from a large database confirmed the natural decline in similar patients, contextualizing the observed improvement.